VIEWS: 4 PAGES: 4 CATEGORY: Medicine POSTED ON: 5/27/2010
Treating dementia-related psychosis is perplexing because of the risk of movement disorders, anticholinergic side effects, and death associated with typical or firstgeneration antipsychotic agents, and cardiovascular, metabolic disturbances, and death associated with SGAs in older adults (Wang et al, 2005). (2005), in a pooled analysis of three randomized, placebo-controlled, double-blind trials in which placebo and risperidone were used (average dose of 1 mg), concluded that SGAs are effective and safe in the treatment of dementia-related psychosis, agitation, and aggression.
Pages to are hidden for
"The Art of Prescribing: Pharmacological Management of Psychosis in Alzheimer's Disease: Clinical Challenges Associated With Second-Generation Antipsychotic Medications"Please download to view full document